Company Profile
ADC Therapeutics Stock Price, News & Catalysts
- Ticker:
- ADCT
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- Switzerland
Stock performance
1.08 USD (-11.48%)
Close
Last updated: October 1, 2026
403M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, ADCT closed down 11.5% at $1.08. No new same-company headline was identified in the current news window.
Company overview
Antibody-Drug Conjugate Company
ADC Therapeutics is a commercial-stage oncology company focused on antibody-drug conjugates. Its capabilities span clinical development, manufacturing, medical affairs, and commercialization, with a current strategic focus on the CD19-directed medicine ZYNLONTA.
ZYNLONTA Commercial Franchise
ZYNLONTA, or loncastuximab tesirine, is approved in the United States and conditionally approved in Europe for relapsed or refractory diffuse large B-cell lymphoma after at least two prior lines of systemic therapy. The company markets the product in later-line disease while working toward broader use and full approval.
Earlier-Line DLBCL Development
LOTIS-5 evaluated ZYNLONTA with rituximab, while LOTIS-7 evaluates ZYNLONTA with glofitamab in relapsed or refractory DLBCL. The company is assessing the regulatory and Phase 3 paths for these combinations following FDA feedback and completion of LOTIS-7 enrollment.
Expansion Across B-Cell Malignancies
Investigator-sponsored studies are evaluating ZYNLONTA in follicular lymphoma and marginal zone lymphoma. These programs may support publication, treatment-guideline inclusion, breakthrough designation requests, and development in disease settings beyond DLBCL.
Focused Commercial and Regulatory Organization
ADC Therapeutics has reorganized around ZYNLONTA's commercial opportunity and the regulatory work needed to sustain and expand the franchise. This narrower structure prioritizes clinical evidence, manufacturing, medical affairs, and market access for a single core asset.
Future catalysts
- Presentation of LOTIS-5, LOTIS-7, and marginal zone lymphoma data at the 2026 ASH Annual Meeting.
- Update on the regulatory strategy and timing for obtaining full approval of ZYNLONTA following the LOTIS-5 pre-sBLA meeting.
- Submission of LOTIS-7 and marginal zone lymphoma data for FDA Breakthrough Therapy designation in 2026.
- Presentation of updated follicular lymphoma data in the second quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ADC Therapeutics (ADCT)?
ADC Therapeutics (ADCT) most recently closed at 1.08 USD, a -11.48% move versus the previous session.
What is the market cap of ADC Therapeutics (ADCT)?
ADC Therapeutics currently has a market capitalization of 403M USD on BioPharmSignal.
What does ADC Therapeutics do?
Antibody-Drug Conjugate Company ADC Therapeutics is a commercial-stage oncology company focused on antibody-drug conjugates. Its capabilities span clinical development, manufacturing, medical affairs, and commercialization, with a current strategic focus on the CD19-directed medicine ZYNLONTA. ZYNLONTA Commercial Franchise ZYNLONTA, or loncastuximab...
On which exchange is ADCT stock listed?
ADC Therapeutics (ADCT) is associated with NYSE, Switzerland, Biopharma.
What is LOTIS-5?
Presentation of LOTIS-5, LOTIS-7, and marginal zone lymphoma data at the 2026 ASH Annual Meeting.
Which conditions is ADC Therapeutics targeting with LOTIS-5?
ADC Therapeutics is associated with oncology based on its company overview and current catalyst commentary.
How does ADC Therapeutics describe recent progress with LOTIS-5?
Presentation of LOTIS-5, LOTIS-7, and marginal zone lymphoma data at the 2026 ASH Annual Meeting.
What is LOTIS-7?
Earlier-Line DLBCL Development LOTIS-5 evaluated ZYNLONTA with rituximab, while LOTIS-7 evaluates ZYNLONTA with glofitamab in relapsed or refractory DLBCL.